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adults with peptic ulcers.1 This could be due to the fact that
not all patients underwent regular follow-up endoscopy .after
apparent healing. In adults it is now well known that many
relapses are entirely asymptomatic and it is possible that the
same applies in children. After initial diagnosis and treatment,
no patient subsequently presented with complications of
gastro-intestinal bleeding or perforation. It would seem that
the consequences of missing an asymptomatic relapse in child-
hood are rarely serious.
In conclusion, although relatively infrequent, peptic ulcers
in childhood are probably more common than generally rea-
lised. Diagnosis of the condition presents a challenge and
demands a high level of awareness if diagnostic delays are to
be avoided. Despite a high index of suspicion some children
will present for the ftrst time with features related to intestinal
blood loss without preceding symptoms. Earlier diagnosis in
these will remain impOssible. In children with abdominal pain
the diagnosis must always be considered' and probably the
most valuab.le clinical clues are localised epigastric tenderness
and anaemia. Failure to consider this possibility in children
presenting with abdominal pain may lead to a considerable
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delay in reaching the correct diagnosis. The conftrmatory
diagnostic investigation of choice is upper gastro-intestinal
tract endoscopy. Where this is not available a barium meal
examination remains an alternative but false-negative studies
occur in a signiftcant number of cases in childhood.6
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Human chorionic gonadotrophin and weight loss
A double-blind, placebo-controlled trial
B. BOSCH, I. VENTER, R. I. STEWART, S. R. BERTRAM
Summary
Low-dose human chorionic gonadotrophin (HCG) combined
with a severe diet remains a popular treatment for obesity,
despite equivocal evidence of its effectiveness. In a double-
blind, placebo-controlled study, the effects of HCG on weight
loss were compared with placebo injections. Forty obese
women (body mass index> 30 kg/m2) were placed on the
same diet supplying 5000 kJ per day and received daily
intramuscular injections of saline or HCG, 6 days a week for 6
weeks. A psychological profile, hunger level, body circum-
ferences, a fasting blood sample and food records were
obtained at the start and end of the study, while body weight
was measured weekly. Subjects receiving HCG injections
showed no advantages over those on placebo in respect of
any of the variables recorded. Furthermore, weight ·Ioss on
our diet was similar to that on severely restricted intake. We
conclude that there is no rationale for the use of HCG
injections in the treatment of obesity.
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Obesity is a common disorder with a strong association with
hean disease, diabetes mellirus, gallbladder disease and pulmo-
nary disorders.1-5 In many societies it is also associated with a
desire to be thin, and many obese individuals are desperate for
an effective method of weight loss and weight maintenance.
Of the many forms of treatment currently available, the use
of low-dose injections of human chorionic gonadotrophin
(HCG) combined with a severe diet has been popular since
1954.6 However, only two srudies have obtained conclusive
evidence that HCG is effective in the treatment of obesityY
In contrast, it has been reported that placebo injections are
as effective as HCG in the treatment of obesity.9,lo Despite the
equivocal evidence relating to the effectiveness of the regimen,
the use of HCG in the treatment of obesity remains popular.
A further reservation for the use of HCG is .he use of a very-
low-kilojoule diet (2100 kJ) as proposed by Simeons,6 which
could produce cardiac and metabolic problems I I and is not
suitable for long-term maintenance treatment.
Simeons7 and Gusman8 claimed that HCG promotes patient
compliance, decreases appetite, facilitates sustained weight
loss, causes differential weight loss from waist and hips, and
releases free fatty acids from depot fat, Gusman8 also reported
that HCG injections caused no adverse side-effects. Stein et
al.,12 however, reported that one previously infertile patient
became pregnant while receiving a course of low-dose HCG
injections. He advised warning all patients receiving HCG for
weight loss to take adequate precautions to prevent pregnancy,
even if they had previously been infertile.
The purpose of this study was to test the validity of the
purported additional benefits of HCG in the treatment of
obesity, using a 'prudent diet' of 5000 kJ per day instead of
the usual very-low-kilojoule diets.
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Fig. 1. Daily energy intake (mean ± SE) was calculated from food
intake records (see 'Methods'). .
ments for the course. Only the results for the panicipants who
successfully completed the course (16 in the saline group and
17 in the HCG group) are reponed. Values are expressed as
mean ± standard error of the mean.
Average daily energy intake
Fig. 1 illustrates the average daily energy intake for the two
groups for the 2 weeks before the study, the fIrst 2 weeks and
the fInal 2 weeks. During the fIrst 2 weeks energy intake was
signilicantly reduced (44,6 ± 5,5% and 44,1 ± 5,5% for the
saline and HCG groups respectively) (P < 0,001). This
decrease in daily energy intake was maintained for the 6-week
period, although there was a slight increase in the energy
intake of both groups in the last 2 weeks (12,9 ± 9,2% and 29,4
± 7,3% for the saline and HCG groups respectively). Although
this increase was signilicant in the HCG group only (P <
0,05), the differences between the two groups were not signili-
cant at any stage during the study.
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Body mass, BM! and body fat
The initial, fmal and percentage changes in body mass, BMI
and body fat for the two groups are shown in Table I. All
values were signifIcantly lower (P < 0,001) at the conclusion of
the study.
Fig. 2 illustrates average weekly body mass for both groups
over the 6-week study period. There were no differences
between the groups in body mass, BMI or percentage body fat
at any stage of the trial.
Subjects and methods
Ethical approval was obtained to conduct a double-blind,
placebo-controlled trial on forty obese white women (body
mass index (BMI) > 30 kg/m2) randomly selected from
volunteers responding to an advenisement in a local news-
paper. Subjects were advised that they would be randomly
assigned to one of two groups of 20, and that they would only
be informed of what injections they had received on conclusion
of the study. One· group received injections of HCG 125 IU in
0,2 ml diluent, in accordance with the recommended dosage,12,13
wliile the control group received .injections of 0,2 ml saline
(placebo). Subjects were all in good health, as determined by a
medical history and examination before commencing the study.
One subject had previously been treated with HCG, more
than 1 year before this study.
The drugs were prepared separately and dispensed in a
double-blind manner utilising a subject code number that was
only broken on completion of the course. Fresh HCG solution
was prepared every 3 days and the solution was stored at 4°C
at all times; individual HCG and saline injections were pre-
pared daily from their respective vials. Intramuscular injections
into the lateral upper arm were given at the same time each
day, 6 days a week for 6 weeks. They were given bya project
leader in order to ensure administration of the treatment. To
be included in the results, patients had to have received a
minimum of 34 of the 36 injections.
Side-effects·of the drugs were reported and recorded daily.
On completion of the programme, subjects were required to
quantitate their experience of pain, both during and after
administration of the injections, on a digital scale of 1 - 5 Cl =
no pain; 5 = very painful).
All subjects were placed on the same balanced diet supplying
5000 kJ per day. Compliance with the diet was assessed using
detailed daily food intake records completed by the subjects
for the 2 weeks before commencement of the course, the fIrst 2
weeks of the course and the fInal 2 weeks. For each 2-week
period, 3 days (2 weekdays and 1 weekend day) were randomly
selected; the average daily energy intake was then calculated
and taken to represent the average intake over the 2-week
period.
Once a week, all subjects attended a lecture on topics such
as the causes and treatment of obesity and behavioural changes
associated with obesity and its treatment. Subjects were
weighed before this weekly lecture.
For the assessment of serum lipid proflles, venous blood
samples were drawn after a l2-hour fast at the stan and on
completion of the course. Body circumferences were measured
at the stan and end of the course by the same examiner using
standard measuring sites and techniques. 14 Using abdomen,
thigh and calf circumferences, body fat percentage was then
calculated according to the method of Katch and McArdle. 14
Subjects also completed a psychological questionnaire speci-
fIcally designed to assess psychological status, including mood
and self-image. Variables were measured on a graded scale of 1
(never) to 5 (always); the lower the score, the more positive the
psychological status. Subjects were also requested to mark
their hunger level on a continuum ranging from 'all the time'
through 'sometimes' to 'never'; the level of hunger was
inverSely related to the recorded score.
The Wilcoxon matched-pairs signed rank test was used for
comparisons within groups (intragroup), while the Mann-
Whi~ey V-test was used for intergroup comparisons.
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Of the original 40 participants, 7 (4 from the saline group and
3 from the HCG group) did not meet the minimum require-
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Fig. 2. Body mass (mean ± SE) recorded weekly.
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TABLE I. BODY MASS, BMI AND BODY FAT MEASUREMENTS
Start End Decrease (%)
Body mass (kg)
Saline
HCG
BMI (kg/m)
Saline
HCG
Body fat (%)
Saline
HCG
96,0 ± 2,7
96,0 ± 2,6
34,79 ± 1,09
35,47 ± 0,77
40,3 ± 1,3
41,S ± 1,3
91,4 ± 2,7*
92,8 ± 2,7*
33,13 ± 1,12*
34,28 ± 0,82*
37,0 ± 1,7*
38,3 ± 1,3*
4,9 ± 0,6
3,4 ± 0,7
4,9 ± 0,6
3,4 ± 0,7
8,4 ± 2,1
7,5 ± 1,5
Final values significantly different from the start
'p< 0,001.
Body circumferences
All body circumferences decreased significantly over the
trial period in both groups, the most significant reductions
occurring in the trunk and thigh regions. There were no
significant differences between the groups at any stage of the
study, and specifically there was no significant additional
reduction of either waist or hip circumferences as a result of
HCG administration (Table II).
Lipid profile
Serum lipid concentrations are summarised in Table Ill.
Only blood cholesterol levels were significantly reduced in
both groups, decreasing from slightly above the normal refer-
ence range (3,8 - 5,7 mmoVl) to within the upper limits
thereof. Although the initial high-density lipoprotein (HDL)/
total cholesterol ratio was significantly higher (P < 0,05) in the
HCG group, the percentage changes in this ratio and in the
HDL/low-density lipoprotein (LDL) cholesterol ratio were
not significantly different between the groups. The mean
HDL/total cholesterol ratios for both groups of women were
unchanged and remained normal (> 0,20) throughout the
study.
Although blood triglyceride concentrations tended to
decrease in all subjects over the 6-week period, changes were
not significantly reduced and values remained within the
upper limits of the normal range (0,97 - 1,97 mmol/l).
Fasting triglyceride and uric acid levels were similar in both
groups, and remained unchanged for the duration of the
study.
Psychological profile
The psychological questionnaire measured mood and self-
image on a scale of 1 (never) to 5 (always), and the lower the
TABLE 11. BODY CIRCUMFERENCES (cm)
Start End Decrease (%)
Neck
Saline 36,7 ± 0,4 36,2 ± 0,4* 1,3 ± 0,3
HCG 36,9 ± 0,5 36,0 ± 0,4** 2,3 ± 0,6
Shoulder
Saline 117,0 ± 1,3 115,0 ± 1,4* 1,7 ± 0,5
HCG 117,8 ± 1,6 116,2 ± 1,5* 1,4 ± 0,4
. Arm
Saline 37,3 ± 0,5 36,4 ± 0,5* 2,3 ± 0,6
HCG 37,7 ± 1,0 36,7 ± 0,9* 2,4 ± 0,5
Chest
Saline 116,3 ± 2,1 112,9 ± 2,1** 3,0 ± 0,4
HCG 114,6 ± 2,1 112,6 ± 2,2** 1,7 ± 0,5
Abdomen
Saline 104,0 ± 2,6 99,8 ± 2,8** 4,2 ± 0,7
HCG 103,5 ± 2,7 99,0 ± 2,5** 4,3 ± 0,8
Hips
Saline 121,5 ± 2,5 116,9 ± 2,6** 3,8 ± 0,5
HCG 122,9 _ 1,7 119,6 ± 1,7** 2,7 ± 0,4
Thigh
Saline 69,1 ± 0,8 66,5 ± 1,0** 3,8 =0,5
HCG 71,8 ± 1,1 69,S ± 1,2** 3,1 ± 0,5
Calf
Saline 41,4 ± 0,7 40,8 ± 0,7* 1,3 ± 0,4
HCG 41,2 ± 0,6 40,6 ± 0,6* 1,3 ± 0,3
Final values significantly different from the start
'p< 0,05.
"P<O,OO1.
188 SAMJ VOL 77 17 FEB 1990
TABLE Ill. LIPID PROFILE
Start End Decrease (%)
Total cholesterol (mmolll)
Saline
HCG
HDLltotal cholesterol
Saline
HCG
HDL/LDL cholesterol
Saline
HCG
Triglycerides (mmolll)
Saline
HCG
Uric acid (mmolll)
Saline
HCG
6,22 ± 0,28
5,81 ± 0,27
0,24 ± 0,01
0,30 ± 0,02t
0,40 ± 0,03
0,55 ± 0,06
1,84 ± 0,23
1,58 ± 0,23
0,29 ± 0,02
0,30 ± 0,01
5,79 ± 0,27*
5,27 ± 0,26*
0,24 ± 0,01
0,29 ± 0,02
0,39 ± 0,03
0,50 ± 0,04
1,52 ± 0,20
1,39 ± 0,19
0,29 ± 0,02
0,32 ± 0,02
-7,50 ± 2,64
- 8,88 ± 2,02
+ 0,46 ± 3,26
- 2,77 ± 2,92
- 1,15 ± 4,05
- 6,00 ± 4,02
- 15,63 ± 6,35
-7,95 ± 6,67
+ 3,11 ± 2,78
+ 3,36 ± 2,72
Final values significantly different from the start
·P<O.Ol.
Significant inter-group difference:
t P< 0.05.
TABLE IV. PSYCHOLOGICAL PROFILE
Start End Improvement (%)
Mood
Saline
HCG
Self-image
Saline
HCG
Hunger level
Saline
HCG
18,6 ± 1,1
19,4 ± 1,0
22,6 ± 1,3
20,6 ± 1,2
3,7 ± 0,6
3,9 ± 0,5
17,2 ± 1,5
17,9 ± 1,4*
20,4 ± 1,4
18,1 ± 1,8*
5,8 ± 0,4*
6,5 ± 0,5**
4,8 ± 8,1
9,6 ± 3,4
9,2 ± 4,4
15,1 ± 4,3
133,0 ± 43,7
225,6 ± 84,0
Final values significantly different from the start
'P< 0.05.
··P<O,Ol.
score the more elevated was the mood and the more positive
the self-image. Although mood was elevated and self-image
was more positive (P < 0,05) at the end of the study in the
HCG group only, there were no significant differences between
the two groups with respect to percentage change (Table IV).
Hunger, on-the' other hand;"was'measured on a scale of 1
(always) to 10 (never), with the result that the recorded score
was inversely related to the level of hunger. On conclusion of
the study, the perception of hunger was significantly and
equally reduced in both groups.
Side-effects
No major side-effects were reported on daily questioning or
in response to a written questionnaire on completion of the
course. Minor side~effects reported included headaches (saline
1, HCG 2), insomnia (saline 1), pruritus (saline 1) and tempo-
rary nocturia (HCG 1). These side-effects were present for
less than 3 days and only occurred during the first week. None
of the subjects developed infections at the injection sites at any
stage of the course or in the 2 weeks after the study.
There was no difference in the pain experienced by the two
groups. On a scale of 1 (no pain) to 5 (extreme pain), the
perceived pain levels were 1,63 ± 0,81 and 1,94 ± 1,24 for the
saline and HCG groups respectively.
Discussion
The major finding of this study was that HCG was no better
than placebo (saline) in promoting weight loss. Furthermore,
none of the claimed additional benefits, namely increased
compliance, decreased appetite and differential weight loss
from the hips and thighs, could be substantiated.
Critique of th.e study
In this study, a diet supplying 5000 kJ per day was used
instead of the very-Iow-energy diets of 2 100 kJ per day6-S,13
originally proposed by Simeons in 1954.6 It has recently been
shown that very-Iow-energy diets lower the resting metabolic
rate,15 thus making weight loss more difficult. Furthermore, a
prudent diet supplying 5000 kJ per day was selected because
we have previously shown16 that it produces an average weekly
weight loss of 0,5 - 1,0 kg but is not associated with the
cardiac and metabolic abnormalities that can occur with very-
low-energy diets. l1 An additional benefit was that it was a
balanced diet that subjects could safely continue on completion
of the course.
In spite of the higher energy equivalent of our diet, average
weight loss over 6 weeks, both for the saline group (5,0 ± 0,5
kg) and for the HCG group (4,1 ± 0,6 kg), compares favourably
with weight loss reported by previous workers over a similar
period of time. Craig et al. 13 reported a total average weight
loss of 2,9 kg (HCG) and 4,0 kg (saline) using a modified
Simeons diet (2300 kJ per day), while Frankl7 reported weight
loss of 5,6 kg (HCG) and 5,1 kg (saline) for subjects on a diet
supplying 4300 kJ per day. It would seem therefore that there
is no particular advantage in prescribing very-low-energy diets.
Furthermore, when the average weight loss in the present
study is compared with the loss reported l6 on this diet alone
(7,0 ± 1,8 kg), on the diet combined with an exercise pro-
gramme (7,0 ± 1,9 kg), or on the diet combined with lecture
therapy (6,3 ± 0,9 kg), it is seen that the injections, whether of
placebo or HCG, had no added effect on weight loss.
Thirty-three of the initial 40 subjects completed the course
of injections despite the inconvenience of daily attendance for
this administration. Three subjects had to withdraw owing to
circumstances beyond their control, but the other 4 subjects
absconded. This drop-out rate is similar to those recorded by
Craig et al. l3 and Stein et al.,J2 but it is significantly lower
than the 35 out of 66 recorded ·by Frank,17 in whose study
injections were administered every other day as opposed to
daily. On first examination, it does not appear that daily
contact with project leaders has an added advantage with
respect to weight loss. However, if it is assumed that subjects
who absconded did not lose weight, the average weight loss in
the Frank investigation would be significantly lower than in
the studies where subjects received injections daily. Thus it
would appear that daily contact promotes compliance and
adherence to the regimen.
Analysis of the results
The various claims made that HCG assists in weight loss by
promoting patient compliance, decreasing appetite and causing
differential weight loss from the waist and hips could not be
substantiated by our fmdings.
Firstly, patient compliance with the diet, as measured by
recorded food intake, was good throughout the course in both
the placebo and the HCG groups, and no advantages of the
HCG could be established. In fact, although there were no
significant intergroup differences, intake increased significantly
in the HCG group over the last 2 weeks of the study.
However, average daily values remained significantly lower
than those recorded before commencement of the study.
Although the improvement in mood and self-image was
statistically significant only in the HCG group, the percentage
changes of the two groups were not different. The elevated
mood and more positive self-image may be ascribed to the
consistent weight losses experienced by these volunteers.
Furthermore appetite, as indicated by the level of hunger, was.
significantly reduced in both groups, in spite of the large
reduction in average daily kilojoule intake. Simeons' claim6
that dietary compliance was assisted by HCG injections as a
result of reduced hunger and a more positive mood could
therefore also not be substantiated in this study.
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No supportive evidence was found for the claim that HCG
enhances differential weight loss from the waist and hips as
reflected by body circumference measurements. The fact that
there were no intergroup differences in fasting triglyceride
levels mitigates against the claim that this alleged differential
weight loss is mediated by an enhanced depot fat mobilisation.
Minimal pain from the injections was experienced by both
groups, thus concurring with Gusman8 that, despite the many
injections administered (> 1500), there were no major side-
effects or infections.
Conclusions
None of the claims made in support of HCG as an aid to
weight loss could be substantiated in this study. Therefore, the
only reason for giving injections would be to motivate the
patient through daily contact with the administrator, and
through regular dietary follow-up. However, since the admini-
stration of injections combined with diet provided similar, if
not identical, effects to combination of a 5000 kJ diet with
weekly lectures,16 the use of daily injections in itself does not
appear to contribute to weight loss. We therefore conclude
that there is no rationale for using this particular form of
therapy in the treatment of obesity.
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